CLINICAL & TRIALS AND STUDIES
S.S Hospital
S.S Hospital conducts rigorous clinical research aimed at evaluating the safety and efficacy of new treatments and medical interventions.
Our clinical trials cover a broad spectrum of diseases and conditions, focusing on improving patient outcomes and advancing standard care protocols.
We follow internationally recognized Good Clinical Practice (GCP) guidelines and maintain strict ethical oversight through an Institutional Review Board (IRB) and Ethics Committee.
Our multidisciplinary clinical research team ensures meticulous planning, monitoring, and analysis of study data to meet high scientific and regulatory standards.
By participating in clinical research, patients have access to cutting-edge therapies and contribute to medical knowledge that benefits the wider community.
Commitment to Patient Safety and Scientific Integrity
Ensuring ethical, high-quality clinical research
All clinical studies at S.S Hospital are conducted with the utmost priority on patient safety and informed consent.
Regular audits and monitoring ensure compliance with regulatory requirements and study protocols.
Our research initiatives aim to translate scientific discoveries into effective medical treatments accessible to patients in need.
Through collaboration with global research networks, S.S Hospital contributes to the advancement of healthcare on a local and international scale.
Clinical Trials Conducted Successfully
An open label study investigating long term safety and tolerability of Nasalfent (fentanyl
Citrate Nasal Spray) in the treatment of Breakthrough Cancer Pain (BTCP) in subjects taking
Regular Opioid Therapy
A Multicentre, Double-blind, double-blind, double-dummy, Two-phase crossover study of
Nasalfent (Fentanyl Citrate Nasal Spray) compared to Immediate Release Morphine Sulphate
Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in subjects taking regular
Opioid Therapy.
A Randomized, open label, two- treatment, two-period, single dose, crossover, bioequivalence
study of intravenous infusion of liposomal doxorubicin 50 mg/m², of Sun Pharmaceutical
Industries Limited India and Doxil 50 mg/m² marketed by Tibotec Therapeutics, A division of
Ortho Biotech, USA in 12 patients with advanced breast cancer/ovarian cancer, under fed
conditions.
Randomized, Phase III-b, Multi-center, Open-label, Parallel study of Enoxaparin (low
molecular weight heparin) given concomitantly with chemotherapy vs chemotherapy alone in
patients with inoperable gastric and gastro-oesophageal Cancer.
Randomized phase 3 Study of Pemetrexed in Combination with Cisplatin in Combination with
Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and
Neck Cancer.
A Phase IIb RCT of Neoadjuvant chemotherapy comparing Paclitaxel, Ifosfamide and Cisplatin
with Paclitaxel and 5-FU in Patients with Locally Advanced Head and Neck Cancer.
An Open Label, Balanced, Randomized, Two Period, Two Treatment, Two Sequence, and Two Way
Crossover Study to Evaluate Safety and Pharmacokinetic Comparison of Intravenous Infusion of
Paclitaxel Lipid Suspension and Taxol® in Patients with Metastatic Breast Cancer "357".
A multicentre, randomized, open label, two-period, two-treatment, two-way crossover,
bioequivalence study comparing Capecitabine tablets 500 mg (Manufactured by Intas
Pharmaceuticals Ltd., India) to the reference listed drug XELODA® 500 mg tablets
(Manufactured by Roche Pharma AG, Germany) in patients of Locally Advanced or Metastatic
Breast Cancer or Metastatic Colorectal Cancer under fed conditions
A multicentre, randomized, open label, two-way crossover, bioequivalence Study comparing
Capecitabine 3 x 500 mg (Intas Pharmaceutical Ltd) to the Reference listed XELODA 3 x 500 mg
in patients with Patients of Metastatic Breast Cancer or Metastatic Colorectal Cancer under
fed conditions "238".
A randomized, Controlled Phase III trial of Picoplatin and Best Supportive Care (BSC) versus
BSC alone in Patients with Small Cell Lung Cancer (SCLC), Refractory or Progressive within
Six Months of Completing First-Line, Platinum-Containing Chemotherapy-Poniard Protocol 0601.
A phase II study to determine the safety, Efficacy, and Pharmacokinetics of Multiple
Intravenous Dose of ALD518 80MG, 160mg Versus Placebo administered to Patients with
Non-Small Cell Lung Cancer Related -Fatigue and Cachexia.
A Randomised, Open-Label, Phase 2 Trial of drug With or Without drug in Patients with
Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer.
A multicentre, randomized, open label, two-period, two-treatment, two-way crossover,
bioequivalence study comparing drug 500 mg in Locally Advanced Breast Cancer or metastatic
Breast Cancer or Colorectal Cancer Patients under fed conditions.
A Randomised, Open-Label, Phase 2 Trial of drug With in Patients with Previously Untreated
Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer.
Open-Label randomized, multidose, parallel study to evaluate efficacy and safety of iv
nanosomal drug lipid suspension and drug.
A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety And Efficacy of
Treating Colorectal Cancer patients with recurrent Metastases Using LitxTM System plus.
Randomized Phase II Clinical Trial of immunotherapy with an allogeneic B7.1/HLA-A1
Transfected Tumor Cell vaccine in patients with Stages IIIB/IV Non Small Cell Lung Cancer
That Have Completed First Line Chemotherapy.
Efficacy and safety of Investigational Test Drug in the treatment of active mild to moderate
ulcerative colitis: A Double Blind Randomized Comparison with Placebo and Asacol Mesalamine
Delayed-Release Tablets (Reference drug) P&G Pharmaceuticals.
Randomized, Phase III-b, Multi-center, Open-label, Parallel study of Enoxaparin (low
molecular weight heparin) given concomitantly with chemotherapy vs chemotherapy alone in
patients with inoperable gastric and gastro-oesophageal Cancer.
A Randomized, Double-Blind Phase III study of Biosimilar of an approved G-CSF and Neupogen
as in an adjuvant to combination chemotherapy with platinum and Etoposide in patient with
Small-Cell Lung Cancer(SCLC).
A Randomized, Double-Blind Phase III study of Biosimilar of an approved G-CSF and Neupogen
as in an adjuvant to combination chemotherapy with Cyclophosphamide, Doxorubicin,
Vincristine and Prednisone with or without rituximab in Patients with Non- Hodgkin Lymphoma
(SCLC).
Randomized Phase II Clinical trial of Immunotherapy with an Allogeneic B7.1/ HLA-A1
transfected Tumor cell vaccine in Patients with Stages IIIB/IV Non-Small cell lung cancer
that have completed first line Chemotherapy.
A double blind randomized single dose, 2-way crossover bioequivalence study of Docetaxel for
Injectable solution (Apotex) and Taxotere (Sanofi-aventis) in Patients with Non- small cell
Lung Cancer (NSCLC) or Breast Cancer.
Protocol No.Lm-LLO-E7-15 A Randomized, active therapy controlled phase 2 study to assess to
safety and efficacy of ADXS11-001 with and without cisplatin as 2nd line therapy for the
treatment of recurrent cervix cancer.
Protocol MAGRIT ADJ 109493: "A double-blind, randomized, placebo-controlled Phase III study
to assess the efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as
adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung cancer".
A Phase III study of ERBB2 Positive advance Or Metastatic Gastric Or Esophageal Or
Gastroesophageal Junction adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with Or
without Lapatinib.
Prevention of Recurrence in Early- Stage, Node-Positive Breast cancer with Low to
Intermediate HER2 Expression with XXXXT™ Treatment.
Magnetic Resonance Imaging in patients with Central Nervous System Lesions
A phase I open label randomized multi center study to determine the maximum tolerated dose
and the dose limiting toxicity of GENOPEP 1 in solid tumor cancer Patients.
A Multicenter, randomized, open label, two treatment, two period, two sequence,
multiple-dose, cross-over, bioequivalence study of Everolimus 10 mg tablet once daily
manufactured by Par Pharmaceutical, Inc. 1 Ram Ridge Road, Spring Valley, NY 10977, USA with
Afinitor (Everolimus) 10 mg tablet manufactured by: Novartis Pharma Stein AG Stein,
Switzerland and Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New
Jersey 07936 in Advanced Renal Cell Carcinoma patients under fasting conditions. (Completed
in 2013).
A multicentre, randomized, open label, single dose, two treatment, two period, two sequence,
crossover, bioequivalence study under fed conditions comparing Imatinib Mesylate tablets 400
mg (Manufactured by – Shilpa Medicare Limited, Pollepally (V), Jadcherla Mandal,
Mahaboobnagar, 509301 India and Manufactured for Ranbaxy Laboratories Limited, India) to the
reference listed drug Gleevec® (Imatinib Mesylate) Tablets 400 mg (Manufactured by -
Novartis Pharma Stein AG, Stein, Switzerland and Manufactured for - Novartis Pharmaceuticals
Corporation, East Hanover, New Jersey-07936) in patients of Philadelphia chromosome positive
Chronic Myeloid Leukaemia (Ph + CML), stabilized on Imatinib Mesylate tablets 400mg.
(Completed in 2012).
A Randomised, Multi- dose, Multi-centre, Comparative Parallel Study to Evaluate Efficacy,
Safety and Pharmacokinetic, Characteristics of Intravenous Infusion of Rituximab (Hetero)
and Reference Medicinal Product (Rituximab, Roche) in Indian Patients of Non- Hodgkin’s
Lymphoma (HERILY Study). (Completed in 2012).
A multicentre, randomized, open label, two-period, two-treatment, two-way crossover,
bioequivalence study comparing Temozolomide capsules 250 mg (Manufactured by: Fresenius Kabi
Oncology Limited, India) to the reference listed drug Temodal (Temozolomide) capsules 250 mg
(Manufactured by : Orion Corporation, Orion Pharma Division, Turku, Finland, Distributed by
Schering-Plough Products Pharmaceuticals Ltd., Brazil) in Glioblastoma Multiforme or
Anaplastic Astrocytoma patients under fasting conditions. (Completed in 2011).
A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare
the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in
Patients with unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (Completed
in 2013).
“A multicenter, open label, balanced, randomized, two-treatment, two- period, two-sequence,
cross-over bioequivalence study of Pegylated Liposomal Doxorubicin HCl injection IV 2 mg/mL
of Intas Pharmaceuticals Ltd., India, with that of Doxil® 2 mg/mL (Doxorubicin HCl Liposome
injection) in ovarian cancer patients whose disease has progressed or recurred after
platinum based chemotherapy under fasting conditions” (Completed in 2013).
“A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the
Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal
Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell
Lymphoma” (Completed in 2012).
A prospective, adaptive, randomized, open-label, multicenter clinical trial to assess the
efficacy and safety of fixed dose combination of capecitabine & cyclophosphamide in patients
of metastatic breast cancer with failure of anthracycline and/or taxane chemotherapy
(Completed in 2013)-